Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Oct;94(4):1496–1505. doi: 10.1172/JCI117489

Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

J G Gilles 1, J M Saint-Remy 1
PMCID: PMC295292  PMID: 7523452

Abstract

Anti-Factor VIII (FVIII) antibodies were prepared by a combination of salt precipitation, gel filtration chromatography, and specific adsorption over insolubilized FVIII from the serum of 10 healthy subjects with normal levels of FVIII. Antibody specificity was confirmed by the capacity to recognize soluble and insolubilized FVIII and to neutralize FVIII cofactor activity in FX activation. Epitope mapping was carried out using a competition ELISA in which affinity-purified human antibodies inhibited the binding of labeled monoclonal antibodies. In most cases, a single region of the A3 domain of the FVIII light chain was recognized by the antibodies, while the reactivity toward heavy chain epitopes differed from one antibody preparation to the other. Sera or IgG fractions of the serum before immunoadsorption over insolubilized FVIII did not bind to FVIII. The IgG fraction that was not retained on the FVIII immunosorbent contained IgG that bound to the variable part of anti-FVIII mouse monoclonal antibodies and inhibited the binding of labeled FVIII; in addition, the IgG fraction inhibited the binding of affinity-purified human antibodies to FVIII, thereby strongly suggesting the presence of anti-idiotypic antibodies. These findings indicate that the presence of anti-FVIII antibodies is a more universal phenomenon than previously thought and that anti-idiotypic antibodies capable of inhibiting the binding of anti-FVIII antibodies to FVIII are produced spontaneously.

Full text

PDF
1496

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Algiman M., Dietrich G., Nydegger U. E., Boieldieu D., Sultan Y., Kazatchkine M. D. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3795–3799. doi: 10.1073/pnas.89.9.3795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avrameas S., Guilbert B., Dighiero G. Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenström's macroglobulinemia may express similar antibody specificities. Ann Immunol (Paris) 1981 Mar-Apr;132C(2):231–236. doi: 10.1016/0769-2625(81)90031-3. [DOI] [PubMed] [Google Scholar]
  3. Ehrenforth S., Kreuz W., Scharrer I., Linde R., Funk M., Güngör T., Krackhardt B., Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992 Mar 7;339(8793):594–598. doi: 10.1016/0140-6736(92)90874-3. [DOI] [PubMed] [Google Scholar]
  4. Foster P. A., Zimmerman T. S. Factor VIII structure and function. Blood Rev. 1989 Sep;3(3):180–191. doi: 10.1016/0268-960x(89)90015-5. [DOI] [PubMed] [Google Scholar]
  5. Gilles J. G., Arnout J., Vermylen J., Saint-Remy J. M. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993 Oct 15;82(8):2452–2461. [PubMed] [Google Scholar]
  6. Guilbert B., Dighiero G., Avrameas S. Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization. J Immunol. 1982 Jun;128(6):2779–2787. [PubMed] [Google Scholar]
  7. Hurez V., Kaveri S. V., Kazatchkine M. D. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol. 1993 Apr;23(4):783–789. doi: 10.1002/eji.1830230402. [DOI] [PubMed] [Google Scholar]
  8. Kavanagh M. L., Wood C. N., Davidson J. F. The immunological characterization of human antibodies to factor VIII isolated by immuno-affinity chromatography. Thromb Haemost. 1981 Feb 23;45(1):60–64. [PubMed] [Google Scholar]
  9. Letter: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975 Dec 15;34(3):869–872. [PubMed] [Google Scholar]
  10. Leyte A., Mertens K., Distel B., Evers R. F., De Keyzer-Nellen M. J., Groenen-Van Dooren M. M., De Bruin J., Pannekoek H., Van Mourik J. A., Verbeet M. P. Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J. 1989 Oct 1;263(1):187–194. doi: 10.1042/bj2630187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McMillan C. W., Shapiro S. S., Whitehurst D., Hoyer L. W., Rao A. V., Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988 Feb;71(2):344–348. [PubMed] [Google Scholar]
  12. Nilsson I. M., Berntorp E., Zettervall O., Dahlbäck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood. 1990 Jan 15;75(2):378–383. [PubMed] [Google Scholar]
  13. Rajewsky K., Takemori T. Genetics, expression, and function of idiotypes. Annu Rev Immunol. 1983;1:569–607. doi: 10.1146/annurev.iy.01.040183.003033. [DOI] [PubMed] [Google Scholar]
  14. Rossi F., Kazatchkine M. D. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989 Dec 15;143(12):4104–4109. [PubMed] [Google Scholar]
  15. Rossi F., Sultan Y., Kazatchkine M. D. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol. 1988 Nov;74(2):311–316. [PMC free article] [PubMed] [Google Scholar]
  16. Rossi F., Sultan Y., Kazatchkine M. D. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol. 1988 Nov;74(2):311–316. [PMC free article] [PubMed] [Google Scholar]
  17. Scandella D., Mattingly M., de Graaf S., Fulcher C. A. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989 Oct;74(5):1618–1626. [PubMed] [Google Scholar]
  18. Schwarzinger I., Pabinger I., Korninger C., Haschke F., Kundi M., Niessner H., Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol. 1987 Mar;24(3):241–245. doi: 10.1002/ajh.2830240303. [DOI] [PubMed] [Google Scholar]
  19. Stel H. V., Sakariassen K. S., Scholte B. J., Veerman E. C., van der Kwast T. H., de Groot P. G., Sixma J. J., van Mourik J. A. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood. 1984 Jun;63(6):1408–1415. [PubMed] [Google Scholar]
  20. Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984 Oct 6;2(8406):765–768. doi: 10.1016/s0140-6736(84)90701-3. [DOI] [PubMed] [Google Scholar]
  21. Svendsen L., Brogli M., Lindeberg G., Stocker K. Differentiation of thrombin- and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitor. Thromb Res. 1984 Jun 1;34(5):457–462. doi: 10.1016/0049-3848(84)90250-0. [DOI] [PubMed] [Google Scholar]
  22. Van Leeuwen E. F., Mauser-Bunschoten E. P., Van Dijken P. J., Kok A. J., Sjamsoedin-Visser E. J., Sixma J. J. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol. 1986 Oct;64(2):291–297. doi: 10.1111/j.1365-2141.1986.tb04122.x. [DOI] [PubMed] [Google Scholar]
  23. Zimmermann R., Kommerell B., Harenberg J., Eich W., Rother K., Schimpf K. Intravenous IgG for patients with spontaneous inhibitor to Factor VIII. Lancet. 1985 Feb 2;1(8423):273–274. doi: 10.1016/s0140-6736(85)91046-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES